Q2 EPS Estimate for Johnson & Johnson Lowered by Analyst

Johnson & Johnson (NYSE:JNJ - Free Report) - Research analysts at Zacks Research decreased their Q2 2025 EPS estimates for shares of Johnson & Johnson in a research report issued on Wednesday, April 30th. Zacks Research analyst K. Shah now expects that the company will post earnings per share of $2.64 for the quarter, down from their previous estimate of $2.69. The consensus estimate for Johnson & Johnson's current full-year earnings is $10.58 per share. Zacks Research also issued estimates for Johnson & Johnson's Q3 2025 earnings at $2.73 EPS and Q4 2026 earnings at $2.78 EPS.

A number of other research analysts have also commented on JNJ. Argus raised Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Bank of America lowered their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Royal Bank of Canada reissued an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Wells Fargo & Company lowered their price target on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $171.82.

Johnson & Johnson Price Performance

JNJ opened at $156.09 on Monday. The stock has a market capitalization of $375.56 billion, a P/E ratio of 23.47, a PEG ratio of 2.56 and a beta of 0.49. The stock has a 50-day moving average price of $158.85 and a 200-day moving average price of $154.54. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. IFS Advisors LLC increased its stake in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares in the last quarter. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new position in Johnson & Johnson in the 4th quarter valued at $29,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth $32,000. Finally, Conquis Financial LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $33,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.33%. The ex-dividend date of this dividend is Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.